News

Pseudomonas Aeruginosa is a complex, formidable bacterial infection that is notoriously difficult to treat, particularly in patients with lowered immune response and who have Cystic Fibrosis. While the bacteria’s mode of operation, which involves targeting and infecting damaged tissue, is relatively well understood, the method by which Pseudomonas Aeruginosa adapts to…

Biopharmaceutical company AbbVie and the non-profit organization Cystic Fibrosis Research, Inc. (CFRI) recently announced a new partnership at the 27th National Family Cystic Fibrosis Education Conference (August 1-3.) The partnership will highlight the CF Chef program, which will help raise both funding and awareness on the…

Positive test results for Vertex Pharmaceuticals’ newest Phase 3 clinical trials may expand the population of cystic fibrosis patients suitable to take a Vertex-produced drug from only 4% to nearly 50%. “It’s going to potentially allow us to get a medicine to 22,000 patients around the world with the…

European Cystic Fibrosis Society (ECFS) president and Cystic Fibrosis Trust professor Stuart Elborn was one of the contributors of the latest breakthrough in cystic fibrosis (CF) research, and he believes that the positive results of two phase 3 studies of the drugs ivacaftor (Kalydeco) and lumacaftor may…

The majority of patients suffering from cystic fibrosis (between 80-90% of the patient population) are affected by exocrine pancreatic insufficiency (EPI), a condition usually present at birth and commonly diagnosed within their first year of life. However, a new experimental therapy for the condition has shown to be…

A fundraising event at the Hyatt Regency Huntington Beach on Saturday, July 19th attracted more than 800 people and became a record-setting fundraising event for the Cystic Fibrosis (CF) Foundation, collecting $1.2 million in donations to help find a cure for the chronic disease. The seventh annual “Pipeline to…

San Francisco based KaloBios Pharmaceuticals, Inc. on Monday released an update on the status of its KB001-A monoclonal antibody development program, including news that multinational Sanofi Pasteur, which had been collaborating with Kalobios on the KB001-A R&D program, is pulling out of the partnership. KaloBios will regain all…

With more than half of the patients with cystic fibrosis developing diabetes and most of them exhibiting insulin insufficiency, researchers at the Chinese University of Hong Kong conducted a study to explain this relationship and suggest a potential treatment strategy for CF-related Diabetes. The study, published this month in…

Findings of new study led by Martina Gentzsch, PhD, at the University of North Carolina School of Medicine and the UNC Marsico Lung Institute in Chapel Hill, N.C. could help drug developers improve compounds designed to correct CFTR proteins in cystic fibrosis (CF) patients. In lab experiments…

Doctors and pharmacists are constantly on the lookout for potential drug interactions when giving patients medication. As a result of a number of recent in vitro cell studies, a few cystic fibrosis treatments may soon be added to the list of interactions. Two independent teams found some cystic fibrosis transmembrane…